Internal Reference Number: FOI_6299
Date Request Received: 17/09/2021 00:00:00
Date Request Replied To: 11/11/2021 00:00:00
This response was sent via: By Email
Request Summary: Dermatology department and Psoriasis treatments
Request Category: Researcher
Question Number 1: Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Apremilast • Bimekizumab • Brodalumab • Certolizumab • Dimethyl fumarate • Etanercept - Enbrel • Etanercept Biosimilar • Guselkumab • Infliximab - Remicade • Infliximab Biosimilar • Ixekizumab • Risankizumab • Secukinumab • Tildrakizumab • Ustekinumab | |
Answer To Question 1: Adalimumab - Humira 5 Adalimumab - Biosimilar 19 Apremilast 2 Bimekizumab 0 Brodalumab 7 Certolizumab 3 Dimethyl Fumarate 0 Etanercept - Enbrel 0 Etanercept - Biosimilar 0 Guselkumab 9 Infliximab - Remicade 0 Infliximab - Biosimilar 0 Ixekizumab 4 Risankizumab 0 Secukinumab 5 Tildrakizumab 1 Ustekinumab 17 | |
Question Number 2: How many patients have been treated for Psoriasis ONLY in the last three months with the following: • Ciclosporin • Methotrexate - any form and strength • Methotrexate injections 15mg and above | |
Answer To Question 2: Unable to answer as we do not have access to information on indication for ciclosporin or methotrexate | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.